Axogen (AXGN) Insider Joseph Tyndall Buys 14,150 Shares

Joseph Tyndall increased his stake in Axogen, Inc. (AXGN) on June 19, 2026, by acquiring 14,150 shares. This transaction was reported to the SEC as a grant or award under a stock option plan. The move comes as part of a flurry of activity from the company's internal leadership, with several other high-level insiders making purchases within the same week.

Broad Insider Buying at Axogen

The purchase by Tyndall is not an isolated event. On June 24, 2026, a large group of insiders also disclosed they were adding shares. Paul Thomas bought 5,579 shares on that date. Five other insiders — Alan Levine, John Johnson, Burke William Mr., Wendell Amy Mcbride, and Joseph Tyndall again — each acquired ,392 shares on June 24. These transactions were not part of a Rule 10b5-1 trading plan, which is a pre-set schedule for buying or selling stock.

Axogen Stock Price Context

Shares of Axogen were trading at $44.69 on Wednesday. The stock has seen a strong recovery from its 52-week low of $15.27, though it remains below its 52-week high of $52.91. Investors often look at moving averages to see long-term trends; Axogen is currently trading at a level that is roughly $6.00 higher than its 200-day average price. The company has a market value of about $2.69 billion.

Recent Earnings and Growth

In its most recent financial reports, Axogen reported annual revenue of $251.17 million. The company is growing its top line, with revenue up 23.1% compared to the prior period. However, Axogen is not yet profitable, posting a net loss that resulted in a negative return on equity of 18.2%. The company’s next earnings report is scheduled for October 28, 2026.

Analysts Set New Price Targets

Wall Street firms have been active in updating their views on the stock. On October 12, 2026, B of A Securities started coverage on the company with a Buy rating and a $52.00 target. Barclays also initiated coverage on October 7, 2026, giving the stock an Overweight rating and a $55.00 price target. Earlier in the fall, Truist Securities adjusted its price target to $53.00 on October 1, 2026, while Raymond James raised its target to $53.00 on September 25, 2026. Currently, the average target price from 10 analysts is $53.90.

Nerve Repair Technology

Axogen focuses on developing surgical solutions for nerve repair. Their products, like the Avance Nerve Graft, help surgeons fix damaged peripheral nerves using processed human tissue. They also make synthetic connectors and protectors to help nerves heal without tension. Based in Florida, the company sells these specialized implants to hospitals and military medical centers for use in complex reconstructive surgeries.

What's Ahead for Axogen, Inc.

While insider buying can signal that leadership is confident in the company's direction, these filings reflect historical trades and do not always predict future stock movement. Investors will likely be watching the October 28 earnings call to see if the company's double-digit revenue growth continues to move it closer to profitability.